-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Indivior Pharmaceuticals, Lowers Price Target to $43

Benzinga·08/05/2026 12:47:40
Listen to the news
Barclays analyst Glen Santangelo maintains Indivior Pharmaceuticals (NASDAQ:INDV) with a Overweight and lowers the price target from $46 to $43.